Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05715047 · ClinicalTrials.gov registry record · NA
Intervention for Fatigue in HCT Recipients
A NA study of Hematologic Malignancy and Hematologic Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT05715047: Recruiting NA study of Hematologic Malignancy and Hematologic Cancer, sponsored by Massachusetts General Hospital.
NCT05715047 is a NA study of Hematologic Malignancy and Hematologic Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 66 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05715047, a NA study of Hematologic Malignancy and Hematologic Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT).
Primary Outcome
Acceptability is defined by at least 80% of participants reporting satisfaction on the Client Satisfaction Questionnaire (range 8-32, with higher scores representing higher satisfaction).
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL CBT for Fatigue
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
What NCT05715047 shows while recruiting
NCT05715047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT05715047 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05715047 about?
NCT05715047 is a clinical study titled "Intervention for Fatigue in HCT Recipients". The purpose of this study is to assess whether a cognitive-behavioral therapy (CBT) for fatigue intervention is acceptable, feasible, and effective at managing fatigue and improving quality of life for patients following hematopoietic stem cell transplant (HCT).
What is the current status of trial NCT05715047?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2023-11-29. Estimated completion is 2026-09-01.
What conditions does trial NCT05715047 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Hematologic Cancer.
What interventions are being tested in trial NCT05715047?
The interventions under investigation include: Usual Care (BEHAVIORAL), CBT for Fatigue (BEHAVIORAL).
Who is sponsoring clinical trial NCT05715047?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05715047 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05715047's enrollment target sits among peer trials
66 20th of 48 higher than 29 of 48 other Hematologic Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
RECRUITING · NA
-
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
RECRUITING · NA
-
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI